Results 11 to 20 of about 409,500 (188)
Surgical Oncology Clinics of North America, 2021 Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030.Effective screening is not available for PDAC, and most ...
Akhil Chawla +3 more
+6 more sources
European Journal of Surgical Oncology, 2023 The need for a common education and training track in surgical oncology across Europe has been emphasized. ESSO provides several hands-on courses for skills training and face-to-face discussions. The core curriculum provides a framework for the overall theoretical requirements in surgical oncology. The UEMS/EBSQ fellowship exam is designed to test core
Kjetil Søreide +4 more
openaire +6 more sources
Nature Reviews Disease Primers, 2016 Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall prognosis that has remained virtually unchanged for many decades. Currently, prevention or early diagnosis at a curable stage is exceedingly difficult; patients rarely exhibit symptoms and tumours do not display sensitive and specific markers to aid detection ...
Kleeff, J +10 more
+10 more sources
Journal of Hematology & Oncology, 2022 Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of ...
Xuhui Tong +8 more
doaj +1 more source
Oncogenesis, 2022 Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Therefore, this
Yunzhen Qian +13 more
doaj +1 more source
World Journal of Surgical Oncology, 2021 Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC).
Yitao Gong +11 more
doaj +1 more source
CA: A Cancer Journal for Clinicians, 1994 Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability.
Michel G. Sarr +3 more
openaire +3 more sources
Cancer Cell International, 2021 Background ALDOA is a glycolytic enzyme found mainly in developing embryos, adult muscle and various malignant tumours, including pancreatic tumours. Our previous study revealed that ALDOA, an oncogene, can promote the proliferation and metastasis of ...
Haidi Chen +11 more
doaj +1 more source